Investigation of Safety and Tolerability of Catumaxomab in Patients With NMIBC

Summary

The purpose of the study is to investigate the safety, tolerability, and preliminary efficacy of the monoclonal bispecific trifunctional antibody Catumaxomab in patients with non-muscle invasive bladder cancer (NMIBC).

Timeline

Start

2020-07-07

Primary completion

2022-12-30

Completion

2023-12-30

Drugs

Indications